C. Baratelli

Pharmacological bioquivalence of branded and generic oxaliplatin: from preclinical assessment to clinical incidence of hypersensitivity reactions in patients with colorectal cancer Background: Generic drugs represent a relevant, potential opportunity in terms of cost savings. However, several physicians are uncomfortable with the replacement of the branded drugs with generic equivalents, indicating among several reasons their hypothetical lower tolerability.

Background: While treatment of localised AC is well established, there is paucity of data to inform the management of patient (pts) with advanced tumours. Thus we have retrospectively analysed treatment pathways and outcomes of a single institution series of advanced AC pts. Methods: Inclusion criteria included epidermoid histology, inoperable locally recurrent or metastatic disease and availability of full medical records. The primary objective was overall survival (OS).

Introduction: Generic drugs, commonly called “generics”, represent a potential opportunity in terms of cost savings, as their costs are usually significantly lower than those of their branded equivalents. However, several physicians are uncomfortable with this replacement, especially because of the suspected lower tolerability of generics. The administration of oxaliplatin is associated to hypersensitivity reactions (HSR) in about 10% of the patients.